QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
NASDAQ:CFMS

Conformis (CFMS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.25
$2.27
50-Day Range
$2.22
$2.26
52-Week Range
$1.05
$7.25
Volume
7,000 shs
Average Volume
99,585 shs
Market Capitalization
$17.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CFMS stock logo

About Conformis Stock (NASDAQ:CFMS)

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.


CFMS Stock News Headlines

CFM Investment JSC CFM
A Weird Income Tactic So Simple and So Lucrative...
It Has Billionaires JOKING About It! There's an unusual income tactic Warren Buffett has relied on time and time again for BILLIONS in dividend payouts. Carl Icahn once joked it was "like taking candy from a baby."  
Computer Forms (Malaysia) Bhd (CFMS)
Durham medtech completes acquisition of public company
A Weird Income Tactic So Simple and So Lucrative...
It Has Billionaires JOKING About It! There's an unusual income tactic Warren Buffett has relied on time and time again for BILLIONS in dividend payouts. Carl Icahn once joked it was "like taking candy from a baby."  
Durham medtech to buy $58M public company
Why Conformis Stock Is Shooting Higher Today
See More Headlines
Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
NASDAQ:CFMS
Employees
295
Year Founded
N/A

Profitability

Net Income
$-50,470,000.00
Pretax Margin
-72.63%

Debt

Sales & Book Value

Annual Sales
$57.06 million
Book Value
$4.07 per share

Miscellaneous

Free Float
7,579,000
Market Cap
$17.80 million
Optionable
Not Optionable
Beta
1.39
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Mark A. AugustiMr. Mark A. Augusti (Age 57)
    CEO, Pres & Director
    Comp: $1.02M
  • Ms. Denise E. Pedulla J.D. (Age 63)
    M.P.H., Chief Legal Officer & Corp. Sec.
    Comp: $443.57k
  • Ms. Christine Desrochers
    Interim CFO & Corp. Controller
  • Mr. Michael Fillion
    Chief Operating Officer
  • Eric Rickenbach
    Sr. VP of US Sales
  • Mr. Terrance Wong
    Sr. VP of Engineering & Regulatory
  • Ms. Erin Henry (Age 38)
    Corp. Controller
  • Dr. Daniel Steines M.D. (Age 54)
    MS, Consultant














CFMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Conformis stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CFMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CFMS, but not buy additional shares or sell existing shares.
View CFMS analyst ratings
or view top-rated stocks.

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) announced its earnings results on Wednesday, November, 3rd. The medical instruments supplier reported ($1.75) earnings per share for the quarter, meeting the consensus estimate of ($1.75). The medical instruments supplier earned $14.25 million during the quarter, compared to analyst estimates of $14.08 million. Conformis had a negative net margin of 72.72% and a negative trailing twelve-month return on equity of 86.46%. During the same quarter in the previous year, the business earned ($2.25) earnings per share.

When did Conformis' stock split?

Shares of Conformis reverse split before market open on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Mark Augusti's approval rating as Conformis' CEO?

15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

When did Conformis IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

This page (NASDAQ:CFMS) was last updated on 2/21/2024 by MarketBeat.com Staff